| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CCNB1; CCNB; G2/mitotic-specific cyclin-B1 |
| Entrez GeneID | 891 |
| WB Predicted band size | Calculated MW: 48 kDa; Observed MW: 55 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic phosphopeptide corresponding to residues surrounding Ser126 of human Cyclin B1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
Phospho-Cyclin B1 (Ser126) antibody is a specialized tool used to detect Cyclin B1 when phosphorylated at serine 126. a post-translational modification critical for regulating its function in cell cycle progression. Cyclin B1. a key component of the cyclin-dependent kinase 1 (CDK1) complex, drives the transition from G2 to M phase by promoting mitotic entry. Its activity is tightly controlled through phosphorylation and degradation. The phosphorylation at Ser126. mediated by kinases such as Aurora A or Plk1. enhances Cyclin B1 stability and facilitates its nuclear translocation, ensuring proper timing of mitotic events. Conversely, dephosphorylation or mutations at this site can disrupt Cyclin B1-CDK1 complex formation, leading to cell cycle arrest or errors in chromosome segregation.
This antibody is widely employed in studies exploring cell cycle regulation, DNA damage response, and cancer biology. Researchers use it in techniques like Western blotting, immunofluorescence, or flow cytometry to assess Cyclin B1 activation status in synchronized cells, mitotic checkpoint studies, or drug screening assays targeting mitotic kinases. Dysregulation of Cyclin B1 phosphorylation is linked to genomic instability and tumorigenesis, making this antibody valuable for investigating therapeutic strategies in cancers with aberrant cell cycle control. Specificity validation via knockout/knockdown models or phosphatase treatment is recommended to confirm signal accuracy.
×
